ABL1 and cancer: Our data also open new avenues for treating other cancers with deregulated tyrosine kinases that block autophagy through BECN1 phosphorylation [32], such as EGFR, HER2, BCR-ABL, and c-KIT among others, especially in cases where existing treatments are ineffective or resistance develops to standard therapies.